This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Fred's Reports September Sales

Fred's, Inc. (NASDAQ:FRED) today reported sales for the five-week fiscal month and eight-month year-to-date period ended September 29, 2012.

Fred's total sales for the month increased 1% to $170.9 million from $169.5 million in September 2011. Comparable store sales for the month declined 3.8% versus an increase of 1.1% in the same period last year.

Fred's total sales for the year-to-date period increased 3% to $1.282 billion compared with $1.244 billion for the same period last year. On a comparable store basis, year-to-date sales declined 1.2% versus an increase of 0.6% in the same period last year.

Commenting on the announcement, Bruce A. Efird, Chief Executive Officer, said, "In September, we experienced the impact of an accelerated shift in sales of brand-name drugs to generics within the pharmacy department. Clearly, the impact of generic pricing on the major brand conversions was dramatic, with the effect on the overall comparable store sales being more than 300 basis points in September. Historically, market changes occur over a period of six to nine months. Consistent with the most recent conversions, these changes have occurred at a much more rapid pace, involving a period of only 30 to 45 days. On a positive note, pharmacy department script count continued to grow, and the department remains on financial forecast.

"General merchandise sales for tobacco, softlines and fall seasonal products also contributed to the lower comparable store sales for September, with tobacco sales accounting for 75 basis points of the decline," Efird continued. "Our key departments such as Pet, Celebration and Party, Auto, Hardware and Food, performed well during the month. As we look ahead, we are positioned for a positive impact on sales from the increased capital investments and marketing spending that we have planned for the last four months of our year. Anticipating an improvement in general merchandise and recognizing the brand-to-generic shift in the pharmacy, we now expect overall comparable store sales for October and third quarter earnings to be in the previously forecasted range."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs